Editorial

Meet the team


Family Practice - a global perspective

The status of health and medicine in the Middle East - disease control


Histopathological relationship between severity of inflammatory reaction in gastritis and intensity of Helicobacter pylori in the antrum

Hypospadias: does the usage of Clomiphene citrate influence the incidence

Level of Hemoglobins in Sickle Cell Trait in Basrah using HPLC


Assure Safer Drug Therapy in the Middle East


An Investigation of Medical staff awareness of patients’ rights in Fasa hospitals and Medical centers

The investigation of effective factors on patients’ satisfaction Parent-Adolescent Relationships in the City of Amol


An epidemiological survey on maternal mortality rate and fatcors contributing to maternal mortality in rural area of Peshawar



Microdilution In Vitro Susceptibility Testing of 71 species of Dermatophytes isolated from pediatric cases in Nigeria against five antifungal agents


Development of Encounter Forms for Cardiovascular Disease Risk Management

 


Abdulrazak Abyad
MD, MPH, MBA, AGSF, AFCHSE

Editorial office:
Abyad Medical Center & Middle East Longevity Institute
Azmi Street, Abdo Center,
PO BOX 618
Tripoli, Lebanon

Phone: (961) 6-443684
Fax:     (961) 6-443685
Email:
aabyad@cyberia.net.lb

 
 

Lesley Pocock
medi+WORLD International
572 Burwood Road,
Hawthorn 3122
AUSTRALIA
Emai
l
: lesleypocock

 


Hypospadias: does the usage of Clomiphene citrate influence the incidence?

 
AUTHOR

Al-Quraan Ghassan MD, Al-Nusirat Bassam MD
Department of Obstetric and Gynecology,
Royal Medical Services

Al-Salaita Ghazi MD
Department of Pediatrics, Royal Medical Services

AL-Maaita Eqab MD
Department of Family Medicine, Royal Medical Services

Al-Quraan Elena MD
Department of Family Medicine, Ministry of health, Jordan

CORRESPONDENCE

Dr. Ghassan Al-Quraan
E-mail: Quraangh @yahoo.com


ABSTRACT

Objectives: To evaluate the link between ovulation induction drug (clomiphene citrate) in pregnancy and the prevalence of hypospadias.

Materials and Methods: A retrospective survey of all cases of hypospadias in the period between the 1st of January 1999 until 31 of December 2003. These cases were collected from the Obstetric-Gynecological Department and the Neonatal Care Unit in the Royal Medical Services Hospitals in the south of Jordan. Odds ratios were calculated for the probability of a genital anomaly (hypospadias) after exposure to clomiphene citrate using conditional logistic regression analysis (95% confidence intervals).

Results: We found a total of 104 cases of hypospdias in all hospitals, 19 ( 0.37% ) of them were those who conceived after ovulation induction by clomiphene citrate, while the remaining 85 ( 0.38% ) were the result of spontaneous ovulation .Cases (19/5119 ) and controls (85/22210) were matched , and odds ratios adjusted for maternal age and birth order were calculated and it was 0.0 for hypospadias associated with clomiphene citrate.

Conclusion: There was no association between clomiphene citrate and external genital malformation specifically Hypospadias .Thus, women exposed to clomiphene citrate after conception, may be assured there is no increased risk of urogenital anomalies (Hypospadias).

Key Words: clomiphene citrate, Hypospadias, ovulation induction.

INTRODUCTION

In this year (2006), nearly 45 years will have passed after the first description of a 'chemically' induced ovulation with clomiphene citrate[1]. Over this period it has maintained a solid footing in reproductive medicine .Worldwide, clomiphene citrate is used for inducing ovulation[2], as it is the first-line therapy for physicians practicing general gynecology when initiating treatment of infertility due to ovulatory dysfunction[3,4].

Clomiphene Citrate is a synthetic, non-steroidal estrogen receptor agonist/antagonist. This anti-estrogenic activity is the mechanism of its action in inducing ovulation. Structurally clomiphene citrate is related to diethylstilbestrol. It has a racemic mixture of two 'isomers', zuclomiphene and enclomiphene. The active isomer is enclomiphene, (trans-isomer with only anti-oestrogenic activity), and has a short half life. On the opposite side, the relatively inactive one (zuclomiphene), has a very long half life. As a result, the half life of clomiphene citrate is about 5 - 7 days, but its metabolites have been found in blood samples on day 22 of the menstrual cycle, and in the faeces up to 6 weeks after administration[5]. In addition, clomiphene citrate displays a tendency for prolonged nuclear receptor occupancy[6] upon repetitive administration ,and this has given rise to speculations about its toxicity and possible teratogenic effects[7].

The extensive experience, gained over a long period of prescribing clomiphene citrate, makes it safe to use ,however , this conclusion is empirical rather than a result of properly designed studies[8], especially in view of the teratogenic and toxic effects that have been described in animals. The aim of our study was to assess the risk of hypospadias among males conceived following the use of clomiphene citrate as an ovulation induction drug.

MATERIALS AND METHODS

A retrospective survey of all cases of hypospadias in the period between the 1st of January 1999 until 31 of December 2003. These cases were collected from the Obstetric-Gynecological Department and the Neonatal Care Unit in the Royal Medical Services Hospitals in south of Jordan. All data was collected from three sources:

 
  • Birth registry in each hospital which contains information on the mother, date and time of delivery , assurance number, the mode of delivery, delivery outcome (male, female and any congenital abnormalities ), midwife name and any comments.
  • Neonatal care unit registry also contains information about the newborn taken by the pediatrician and staff nurse.
  • Pharmacy registries in selected hospitals which contain data on all prescriptions for clomiphene citrate (Clomid ). All mothers with epilepsy, diabetes and those diagnosed with pre-eclampsia were excluded from this study, as it has been associated with increased risk for hypospadias. Also mothers other than Jordanians (immigrant ) were excluded from this study as some countries of origin (e.g. Turkish) have an increased risk for hypospadias.

In this population based case-control study , odds ratios were calculated for the probability of a genital anomaly (hypospadias) after exposure to clomiphene citrate using conditional logistic regression analysis adjusted for maternal age and birth order (95% confidence intervals).

RESULTS

Of the 27,329 male newborns that were enrolled in this population based case - control study, we found a total of 104 cases of hypospdias in all hospitals. Cases were distributed into two groups; those who conceived after ovulation induction by clomiphene citrate 0.37% (19/5119), and those, control groups, who conceived spontaneously 0.38% (85/22210).

Odds ratios were calculated for the probability of a genital anomaly (hypospadias) after exposure to clomiphene citrate using conditional logistic regression analysis adjusted for maternal age and birth order, and it was 0.0 for hypospadias associated with clomiphene citrate. ( see Table I).

The analysis of these results revealed that, there was no significant differences between the two groups in the incidence of hypospadias (0.37%) compared with (0.38%) in the control one.

Thus fear of hypospadias in women conceived after clomiphene citrate, or who used it incidentally during early pregnancy can be reduced towards the null, as seen in figure -1

DISCUSSION

Embryologic formation of the penile urethra takes place between 9 and 12 weeks after ovulation and depends on the secretion of testosterone by the fetal testes[9], and by 12-14 weeks gestation, differentiation of internal genital ducts and external genitalia along either male or female is complete[10], therefore, we considered exposure during the 1st trimester to be most important.

Hypospadias is a developmental anomaly considered one of the most prevalent urogenital malformations, the etiology of which, is still not clearly understood11,and affects 1 in 250 male newborns[12].

In 2002, an increased risk of hypospadias was reported for sons of women exposed to diethyl-stilbestrol (DES) in utero, which is a non-steroidal estrogen, and nowadays it is no longer used in obstetric patients of childbearing age. Because of the fact that clomiphene citrate and DES are related structurally, the latter was reported to be responsible for the appearance of clear cell adenocarcinoma of the vagina of female offsprings[13], and the development of benign epididymal cysts in DES-exposed men [14-19] , fear about clomiphene citrate teratogenicity and concern has been raised over a possible increase in disorders of the male reproductive tract, specifically hypospadias.

Fortunately, clomiphene citrate is a well tolerated drug (in 1997 only one of 113 patients dropped out because of drug side-effects in a study by Kousta et al [20]). According to our knowledge of current literature, the potential effects of clomiphene on the fetus have been investigated in animal studies, while others (human studies) investigate the effect of sex hormones exposure to the urogenital system as shown in Table II.

The overall clinical experience up till now indicates that the use of clomiphene citrate is associated with an incidence of birth defects similar to that observed in the general population[20,21]. Similar observation was reported in our study in which there was no significant differences between the two groups in the incidence of hypospadias (0.37%) compared with (0.38%) in the control one.

At the present time, despite the fact that all collected data was based on routine daily records, and while the comparison must be interpreted cautiously in light of possible selection bias, it may be concluded that clomiphene citrate is not associated with any increased risk of hypospadias.

CONCLUSION

In this study, we found that, there was no association between clomiphene citrate and external genital malformation specifically Hypospadias. Thus, women exposed to clomiphene citrate after conception, may be assured there is no increased risk of urogenital anomalies (Hypospadias).

 

Table 1. Characteristics of 104 boys with hypospadias and 22210 control population.

  Without Hypospadias With Hypospadias Total Crude Odds Ratio Adjusted Odds Ratio Risk Ratio
With Clomiphene 5100 19 5119 0.9697 - 0.9698
Without Clomiphene 22125 85 22210      
Total 27225 104 27329 0.9697 0 0.9698

Table 2. Effects of sex hormones on genitalia, case-control and cohort studies.

Reference No. Authors Genital changes investigated Sex hormonesexposure
22 Sweet et al, 1974 Hypospadias Estrogen, hydroxyprogesteronecaproate
23 Harlap et al, 1975 Hypospadias Hydrocele cryptorchidism Estrogen, progesterone, abortifients
24 Mau, 1981 Hypospadias Progestin / (pregnancy test)
25 Monteleone et al , 1981 Hypospadias Sex hormones (not specified)
26 Polednak and Janerich, 1983 Hypospadias Hormonal pregnancy tests, supportive hormones, oral contraceptive pills
27 Kallen, 1988 Hypospadias Oral contraceptive pills

Figure 1. Effects of sex hormones on genitalia, case-control and cohort studies.

 


REFERENCES
1. Greenblat , R.B. (1961) Chemical induction of ovulation.Fertil. Steril., 12,402- 404.
2. Furr BJ ,Woodburn JR. Luteinizing hormone-releasing hormone and its analogues : a review of biological properties and clinical uses.J Endocrinol Invest 1988 ;11 :535-57 .
3. Gysler M, March CM, Mishell Jr DR, et al.A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test.Fertil Steril 1982;37:161-7.
4. ACOG Practice Bulletin. Management of Infertility Caused By Ovulatory Dysfunction.2002;34.
5. Geier A , Lunenfeld B , Pariente C , Kotev - Emeth S , Cadmic A , Kokia E , et al. Estrogen receptor binding material in blood of patients after clomiphene citrate administration :determination by radioreceptor assay . Fertil Steril 1987;47:778-84
6. Clark, J.H. and Markaverich, B.M. (1982) The agonistic-antagonistic properties of clomiphene :a review. Pharmacol.Therapeut.,15 467-519.
7. Adashi, E.Y. (1993) Clomiphene citrate :the case for monoisomeric preparation.Baillieres Clin. Obstet. Gynaecol.,7,331-347.
8. Greenland, S. and Ackerman, D.L. (1995) Clomiphene citrate and neural tube defects: a pooled analysis of controlled epidemiologic studies and recommendations for future studies.Fertil. Steril. , 64, 936-941.
9. O´Rahilly R , Muller F. Human Embryology and Teratology. New York, NY:John Wiley and Sons ;1992.
10. Fanaroff AA, Martin RJ ,eds.Neonatal-perinatal medicine: Disease of the fetus and infants.4th ed. St.Louis:CV Mosby , 1987.
11. Manson JM, Carr MC 2003 Molecular epidemiology of hypospadias :review of genetic and environmental risk factor. Birth defects Res A Teratol 67 :825 - 83.
12. Nelson , Textbook of Pediatrics 17th edition , Behrman R.E. ,Kliegman R.M. , Jenson H.B. ,2004 ;1812.
13. Herbst AL, Ulfelder H, Poskanzer DC .Adenocarcinoma of the vagina .Association of maternal stilbestrol therapy with tumor appearance in young women.N Engl J Med 1971 ; 284:878-81.
14. Bibbo M , Gill WB ,Azizi F , Blough R , Fang VS , Rosenfield RL , et al. Follow-up study of male and female offspring of DES-exposed mothers. Obstet. Gynecol. 1977; 49 :1-8 .
 
15. Leary FJ , Resseguie LJ , Kurland LT , O'Brien PC , Emslander RF , Noller KL . Male exposed in utero to diethylstilbestrol .JAMA 1984 ; 252:2984-9.
16. Gill WB , Schumacher GF , Bibbo M , Straus FH , Schoenberg HW ,. Association of diethylstilbestrol exposure in utero with cryptorchidism, testicular hypoplasia and semen abnormalities . J Urol 1979 ;122 :36-9.
17. Wilcox AJ , Baird DD , Weinberg CR , Hornsby PP , Herbst AL. Fertility in men exposed prenatally to diethylstilbestrol. N Engl J Med 1995; 332 :1411-6.
18. Niculescu A. Effect of in utero exposure to DES on male progeny. J Obstet Gynecol Neonatal Nurs 1985;14: 468-70.
19. Conley GR , Sant GR , Ucci AA Mitcheson HD . Seminoma and epididymal cysts in a young man with known diethylstilbestrol exposure in utero. JAMA 1983; 249 :1325-6.
20. Kousta , E., White, D.M. and Franks , S.(1997) Modern use of clomiphene citrate in induction of ovulation. Hum. Reprod. Update, 3, 359-365.
21. Adashi , E.Y. (1996) Ovulation induction :clomiphene citrate . In Adashi, E.Y., Rock, J.A. and Rosenwaks, Z.(EDS), Reproductive Surgery and Technology. Lipincott-Raven , Philadelphia, USA, pp .1182-1206.
22. Sweet RA, Schrott HG, Kurland R, Culp OS. Study of the incidence of hypospadias in Rochester, Minnesota, 1940-1970, and a case control comparison of possible etiologic factors. Mayo Clin Proc 1974;49:52-8.
23. Harlap S , Prywes R,Davies AM . Birth defects and estrogens and progesterones in pregnancy. Lancet 1975; i:682-3.
24. Mau G . Progestins during pregnancy and hypospadias. Teratology 1981; 24 :285-7.
25. Monteleone RN, Castilla EE , Paz JE. Hypospadias : An epidemiological study in Latin America. Am J Med Genet 1981 ;10:5-19.
26. Polednak AP , Janerich DT . Maternal characteristics and hypospadias :A case control study. Teratology 1983 ; 28 :67-73.
27. Kallen B. Case- control study of hypospadias on registry information. Teratology 1988 ; 38 :45-50.